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ABSTRACT 
Objective 
To evaluate the feasibility of day and night closed-loop insulin delivery in adults with 
type 1 diabetes under free-living conditions. 
 
Methods 
Seventeen adults with type 1 diabetes on insulin pump therapy [age 34±9years; 
HbA1c 7.6±0.8%; duration of diabetes 19±9years; mean±SD] participated in an open-
label multinational three-centre cross-over study. In a random order participants 
underwent two eight day periods (first day at the clinical research facility followed by 
seven days at home) of sensor augmented insulin pump therapy or automated 
closed-loop insulin delivery. The primary endpoint was the time when sensor glucose 
was in target range between 3.9 and 10.0 mmol/l during the seven day home phase.  
 
Results 
During the home phase, the percentage time when glucose was in target range was 
significantly higher during closed-loop compared to sensor augmented pump therapy 
(75 [61, 79] vs. 62 [53, 70]%, median [IQR], p=0.005). Mean glucose (8.1 vs. 8.8 
mmol/l, p=0.027) and time spent above target (p=0.013) were lower during closed-
loop while time spent below target was comparable (p=0.339). Increased time in 
target was observed during both day-time (p=0.017) and night-time (p=0.013).  
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Conclusions 
Compared to sensor augmented pump therapy, one week closed-loop insulin 
delivery at home reduces mean glucose and increases time in target without 
increasing the risk of hypoglycaemia in relatively well controlled adults with type 1 
diabetes. 
 
Keywords: type 1 diabetes, closed-loop insulin delivery, model predictive control, 
continuous subcutaneous insulin infusion, continuous glucose monitoring, artificial 
pancreas 
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Despite significant improvements in the care of type 1 diabetes, achieving 
good glycaemic control while avoiding hypoglycaemia (1) remains a challenge for 
many patients (2; 3). Insulin pump therapy and real time continuous glucose 
monitoring (CGM) have shown to improve HbA1c (4; 5) and reduce hypoglycaemia 
(6; 7) particularly when using low glucose suspend (8; 9). Closed-loop insulin delivery 
is an emerging treatment option combining these technological advances (10) to 
modulate delivery of insulin in a glucose responsive fashion. Closed-loop differs from 
conventional pump therapy, characterised by pre-programmed basal delivery, 
through the use of a control algorithm which directs subcutaneous insulin delivery 
according to sensor glucose levels. Several studies have evaluated the safety and 
efficacy of closed-loop under laboratory conditions and shown promising results. 
These include evaluations using a randomised design by our group in youths (11; 
12), adults (13), and pregnant women (14) and by others using the model predictive 
control algorithm (15; 16), the proportional-integral-derivative approach (17; 18), and 
the fuzzy logic controller (19; 20). Insulin and glucagon co-administration have also 
been applied in  studies (21-23). 
In contrast to studies conducted in the clinical research facility with carefully 
controlled conditions, closed-loop at home is exposed to considerably more varied 
meal and exercise patterns. Participants may over- or underestimate carbohydrate 
content and may undertake unplanned activity and/or exercise. Patients using insulin 
pump therapy are advised to use temporary reductions or increments of basal insulin 
delivery to meet these demands but this requires a degree of planning and user 
intuition and interaction. Since closed-loop systems modulate delivery of insulin in a 
glucose responsive fashion (10), it may be able to achieve better glucose control 
than pre-programmed basal rates of conventional pump therapy. 
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In February 2010, the European Union granted funding to the  AP@home 
consortium of European academic medical centres, biotechnology companies and 
industrial partners to carry out closed-loop glucose control research (24). The first 
major closed-loop study performed by the AP@home consortium evaluated the 
feasibility of day and night closed-loop insulin delivery using two different algorithms 
in 47 adults with type 1 diabetes (25). The present study was undertaken to evaluate 
the performance of day and night closed-loop insulin delivery with Cambridge 
algorithm over seven days at home preceded by one day control at the clinical 
research facility. 
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METHODS  
Participants and study design 
The study adopted an open-label prospective multinational three-centre 
randomised cross-over design. The study protocol was approved by respective 
research ethics committees and regulatory authorities in the UK, Germany and 
Austria. Study participants were recruited between January 2013 and August 2013 
through adult diabetes clinics and other established methods at each participating 
centre (Addenbrooke's Hospital, Cambridge, UK; Profil Institute, Neuss, Germany; 
and Medical University of Graz, Graz, Austria). Key inclusion criteria were age ≥18 
years, diagnosis of type 1 diabetes, treatment with insulin pump therapy for at least 
3 months, willingness to perform at least six finger-stick glucose measurements per 
day, and HbA1c ≤10% (86 mmol/mol). Key exclusion criteria were concurrent illness 
or medications likely to interfere with interpretation of study results, recurrent severe 
hypoglycaemia, significant hypoglycaemia unawareness, total daily insulin dose ≥ 2.0 
U/kg, clinically significant nephropathy, neuropathy, or retinopathy, severe visual or 
hearing impairment, pregnancy and breast feeding. All participants provided written 
informed consent prior to study related activities.  
 
Study procedures: 
After enrolment, participants were trained on the use of study insulin pump 
(Dana R Diabecare, Sooil, Seoul, South Korea) and continuous glucose monitoring 
device (FreeStyle Navigator, Abbott Diabetes Care, Alameda, CA, USA) (26). The 
study insulin pump was programmed with participant’s usual basal settings as well as 
usual insulin to carbohydrate ratios and correction factors. Participants were advised 
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to use the bolus calculator for all meals during the entire study period. Ability to use 
study devices was formally assessed using competency assessment and additional 
training was provided as required. After a run-in period of seven days to three weeks, 
participants underwent two eight day periods; in random order, when glucose was 
controlled either by sensor augmented insulin pump therapy (SAP) or closed-loop 
insulin delivery. The first day of each study period was conducted at a clinical 
research facility. After the first day, participants continued study interventions for the 
next seven days under free-living conditions in their home and work environment. 
The two intervention periods were separated by a one to four week washout. No 
changes were made to usual treatment parameters. Participants were advised to 
calibrate the CGM device according to manufacturer’s instructions (26) and use the 
built-in glucometer for all finger-stick measurements and to keep a diary for detailed 
documentation.  
 
Inpatient stay 
At the start of each study intervention, participants were admitted to the 
clinical research facility around 07:30 hours. On arrival, an intravenous cannula was 
inserted to allow for frequent venous sampling starting at 08:30 hours. Venous blood 
samples were collected at 30 minute intervals for the measurement of plasma 
glucose between 08:30 and 23:00 hours followed by every 60 minutes thereafter till 
07:00 hours the following morning. Closed-loop and SAP treatment commenced at 
09:00 hours with breakfast. 
Participants consumed standardized meals; breakfast 50 g, lunch 60 g and 
dinner 80 g of carbohydrates; at 09:00, 13:00 and 20:00 hours. Fifteen minutes 
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before each meal an insulin bolus was delivered, calculated according to usual 
settings and pre-meal finger-stick glucose levels. The insulin bolus was given with 
the meal if finger-stick glucose was ≤4.0 mmol/l. Meal content and bolus procedure of 
each study intervention was identical. Participants consumed optional snacks 
containing 20g carbohydrate at 16:00 hours and 15g carbohydrate at 22:00 hours. 
During the closed-loop visit, no insulin bolus was given for snacks but during the SAP 
visit participants received pre-snack bolus as per usual practice. Rapid-acting insulin 
analogue aspart (Novo Nordisk, Bagsvaerd, Denmark) was used throughout the 
study. During the closed-loop visit, participants received additional training on 
starting, stopping, and safe operation of the closed-loop system. Competency on the 
use of closed-loop system was assessed by the study team prior to discharge. 
 
Home phase 
Seven day home phase commenced at the end of the one day inpatient stay. 
Participants were provided with a custom made pouch to carry the small portable 
computer running the algorithm and CGM device (Supplemental Online Material, 
Figure S1). As a precaution, participants were advised not to drive or undertake 
strenuous physical exercise while the closed-loop system was in operation but were 
encouraged to engage in usual daily activities including going to work and moderate 
activity such as walking and daily housework. Participants were provided with a 24-
hour telephone helpline and were advised to follow usual treatment guidelines during 
inter-current illness, hyperglycaemia and hypoglycaemia. They were free to consume 
meals of choice including eating out. During closed-loop intervention, participants 
were not required to give insulin bolus for snacks below 30 g of carbohydrate and 
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during both study interventions participants were free to decide on alarm thresholds 
for the CGM device. 
 
Closed-loop system  
The Florence closed-loop system (University of Cambridge, Cambridge, UK) 
(27) comprises a model predictive control algorithm residing on an ultraportable 
laptop (OQO Model 02 computer, OQO, CA, USA), which is linked to the CGM 
receiver by a USB cable and controls the study pump over wireless communication. 
Every 12 minutes, the algorithm calculated a new insulin infusion rate which was 
automatically sent to the study insulin pump. The calculations utilised a compartment 
model of glucose kinetics (28) describing the effect of rapid-acting insulin analogues 
and the carbohydrate content of meals on glucose levels. Participants were required 
to count the carbohydrates and use the pump bolus calculator for pre-meal boluses 
as per usual practice. Meal bolus also included a correction bolus as calculated by 
the bolus wizard if the glucose was outside target range.   
Carbohydrate content of consumed meals and insulin delivery history 
including manually instructed bolus, were downloaded automatically from the study 
pump.  The algorithm was initialized using pre-programmed basal insulin delivery 
downloaded from the study pump. Additionally, participant’s weight and total daily 
insulin dose were entered at setup. During closed-loop operation, the algorithm 
adapted itself to a particular participant. The treat-to-target control algorithm aimed to 
achieve glucose levels between 5.8 and 7.3 mmol/l and adjusted the actual level 
depending on fasting vs. postprandial status and the accuracy of model-based 
glucose predictions. A sample 24 hour section of closed-loop study arm is shown in 
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Supplemental Online Material Figure S2 and interface of the closed-loop system is 
shown in Supplemental Online Material Figure S3. Algorithm version 0.3.24 with 
interface version 1.0.7 was used (University of Cambridge, Cambridge, UK). 
 
Safety precautions during closed-loop 
Participants were trained to perform calibration check before breakfast and 
evening meal. If sensor glucose was above finger-stick glucose by more than 3 
mmol/l, the CGM was re-calibrated. There was no re-calibration for sensor under 
reading. These instructions resulted from an in silico evaluation of hypoglycaemia 
and hyperglycaemia risk (29) using the validated Cambridge simulator (30).  
If sensor glucose became unavailable, pre-programmed insulin delivery was 
automatically restarted within 30 minutes or within 1 hour in case of other failures. 
This limited the risk of insulin under- and over-delivery (29). Safety rules limited 
maximum insulin infusion and suspended insulin delivery at sensor glucose at or 
<4.3mmol/l or when sensor glucose was rapidly decreasing.  
 
Assays  
During the in-patient stay, a YSI2300 STAT Plus Analyzer (YSI, Lynchford 
House, Farnborough, UK; intra-assay coefficient of variation (CV) 1.5% and inter-
assay CV 2.8%) was used for determination of plasma glucose.  
 
Statistical analysis  
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The analysis plan was agreed in advance. All analyses were undertaken on 
intention to treat basis. The primary outcome was the time when glucose was in the 
target range 3.9 to 10.0 mmol/l during the home study phase. Secondary outcomes 
were mean glucose, time when glucose was <3.9 mmol/l and <2.8 mmol/l 
(hypoglycaemia), time when glucose was >10.0 mmol/l and >16.7 mmol/l 
(hyperglycaemia), low and high blood glucose index and insulin delivery. We 
estimated glycaemic variability by the standard deviation of glucose and the 
coefficient of variation. The low and high blood glucose index assessing the duration 
and extent of hypo- and hyperglycaemia  was calculated as an average of 
transformed glucose measurements progressively increasing at low and high glucose 
levels (31). We corrected for bias resulting from simultaneous use of sensor glucose 
to direct insulin delivery and to assess outcomes by using adjusted glucose - a 
stochastic transformation of glucose metrics when assessing time glucose was in, 
below, and above target range (32). Other glucose metrics such as mean glucose 
and glucose variability were calculated utilising native (unadjusted) sensor glucose 
levels. 
Secondary outcomes were calculated for the one day inpatient stay, seven day home 
phase as a whole and daytime (07:00 till 23:00 hours) and overnight (23:00 till 07:00 
hours) periods. During the inpatient stay, study outcomes were calculated using both 
YSI laboratory glucose measurements and sensor glucose. Calculations were made 
using GStat software, Version 2.0 (University of Cambridge). Statistical analyses 
were conducted with the use of SPSS, Version 19 (IBM Software, Hampshire, UK). 
Normally distributed data were compared using paired t-test while non-normally 
distributed data were compared using Wilcoxon signed rank test. Values are reported 
as mean±SD or median (interquartile range: quartile 1 to quartile 3) unless stated 
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otherwise. All p-values are two-tailed and values less than 0.05 were considered 
statistically significant. 
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RESULTS 
From January 2013 to August 2013, 24 volunteers were screened and 21 
enrolled. Four dropouts were recorded, two during the first study period, one during 
the run-in phase, and another during the washout period leaving 17 completed 
participants [age 34±9 years; HbA1c 7.6±0.8%; duration of diabetes 19±9 years; 
duration of pump therapy 5.6±6.9 years; Supplemental Online Material Table S1].  
 
Glucose control and insulin delivery during the home phase 
The primary study outcome, the adjusted time spent in target glucose range 
3.9 to 10.0 mmol/l at home, was higher during closed-loop insulin delivery (74.5 
[61.1, 78.9] vs. 61.8 [53.3, 70.1]%, p=0.005, Table 1). Closed-loop reduced mean 
glucose (8.1±1.0 vs. 8.8±1.0 mmol/l, p=0.027) and the adjusted time spent above 
target glucose level (21.9 [16.7, 32.3] vs. 30.5 [24.3, 41.4] %, p=0.013), without 
increasing the time spent in hypoglycaemia. Measured as the standard deviation, 
variability of glucose was lower during closed-loop (2.9±0.6 vs. 3.3±0.8, p=0.034)   
but no difference was observed using the coefficient of variation (35.7±5.9 vs. 
37.7±7.6, p=0.149). Sensor glucose profiles during the two treatments periods are 
shown in Figure 1 with particularly pronounced difference during the overnight period. 
Fourteen participants (82%) showed increased time in target during closed-loop 
compared to SAP (Figure 2). Native sensor glucose levels (Supplemental Online 
Material Table S2) concurred with the assessment by adjusted values (Table 1). 
As expected, variability of basal insulin delivery was significantly higher during 
closed-loop (Table 2). Bolus and basal insulin infused during day was significantly 
different between the two interventions; during closed-loop period lower bolus 
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amount and higher basal dose were observed. Overall there was tendency towards 
lower total daily dose during closed-loop but this did not reach statistical significance 
(p=0.109).  
 
Day and night glucose control during the home phase 
Closed-loop increased time in target during both day-time (target 3.9 to 10.0 
mmol, 72.5% vs. 65.4%, p=0.017) and night-time (target 3.9 to 8.0 mmol/l, 48.4% vs. 
35.1%, p=0.013) (Table 2). In addition, mean sensor glucose was lower during night-
time period (8.3 ± 1.3 vs. 9.3 ± 1.1, p=0.015). There was no difference in the area 
under the curve for hypoglycaemia during either period (Table 2). 
 
Glucose control and insulin delivery during the one day inpatient stay 
Time spent in target glucose range 3.9 to 10.0 mmol/l was higher with closed-
loop during the inpatient stay (YSI based results Table 1 and CGM based results 
Supplemental Online Material Table S3). The number of rescue carbohydrate 
treatments required was lower during closed-loop (closed-loop 7 vs. SAP 16) but did 
not reach statistical significance (p=0.215). Closed-loop administered significantly 
lower total insulin daily dose during the inpatient stay (36.8 vs. 41.8 U, p=0.028). 
 
Sensor accuracy during inpatient stay 
Sensor performance was good with median absolute deviation of 0.8 (0.4, 1.3) 
mmol/l and median absolute relative deviation (MARD) of 10.0% (4.7, 16.3). Detailed 
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clinical and numerical sensor accuracy is shown in Supplemental Online Material 
Table S4. Eighty three percent of YSI-sensor pairs were in Clarke Error Grid Zone A.  
 
 
Adverse events 
Two severe hypoglycaemic events occurred during the study; one event 
during closed-loop arm and one event during washout period. The severe 
hypoglycaemia event during the closed-loop period occurred at a time when closed-
loop was non-operational due to sensor unavailability and insulin was being delivered 
according to participant’s usual pump settings. The second severe hypoglycaemia 
episode leading to hospital admission occurred during washout while the participant 
was using usual pump treatment in the context of inter-current illness. Both 
participants fully recovered with no clinical sequela. Both episodes most likely 
resulted from over aggressive manual insulin bolus corrections. Four episodes of 
high glucose occurred due to infusion set failure (no significant ketosis). One 
participant suffered from a transient vasovagal episode during the one day in-patient 
stay and fully recovered with intravenous fluid treatment. 
 
Utility analysis 
During the one day inpatient stay closed-loop was operational 98.4 [95.8, 100] % of 
time. During home phase closed-loop operational time was 83.0 [71.1, 92.3] %. 
Availability of CGM during home phase was 95.0 [85.2, 97.8] % during closed-loop 
and 95.1 [92.6, 97.4] % during SAP. Closed-loop operational time when CGM data 
were available was 90.9 [83.7, 96.2] %. 
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Reasons for not using closed-loop during home phase included unavailability 
of CGM data, periods of driving and strenuous exercise, non-operational laptop, and 
unreliable Bluetooth communication between pump and the computer. Detailed 
analysis of failure events is shown in Supplemental Online Material Table S5. The 
most common reason for undesired cessation of closed loop was failure of Bluetooth 
pump communication. In total there were 91 instances of pump communication 
failures giving a mean interval between failures of 25.6 hours. Out of the 91 instances 
47 instances were recorded in 3 participants. Excluding these 3 participants the 
mean interval between pump communication failures was 53 hours. 
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CONCLUSIONS  
The present study demonstrates the feasibility of unsupervised day and night 
closed-loop insulin delivery under free-living conditions in adults with type 1 diabetes. 
When applied in a relatively well controlled cohort, compared to current best therapy, 
closed-loop increased the time when glucose was in the target range while reducing 
the mean glucose. Importantly, these improvements were achieved without 
increasing the risk of hypoglycaemia  while administering similar amount of  total 
daily insulin dose. Benefits of closed-loop were more pronounced during the 
overnight period although glucose control was superior during both day and night 
time. Other benefits include  reduced glucose variability as measured by standard 
deviation and reduced high glucose excursions. In agreement with results obtained 
during the seven day home phase, participants also showed improved plasma 
glucose control with closed-loop during the one day stay at the clinical research 
facility while infusing a significantly lower amount of insulin.  
In the current study there was no statistically significant decrease in the time 
spent in hypoglycaemia. This can be explained by the study not being powered to 
detect such a difference although trend towards a lower hypoglycaemia exposure 
was observed (AUC below 3.5 mmol/l 71% lower during closed-loop; 2.9% vs 7.9%, 
CL vs SAP; p=0.14). Low levels of hypoglycaemia were observed compared to, for 
example, Juvenile Diabetes Research Foundation CGM trial (5) which recorded time 
spent in hypoglycaemia (< 3.9 mmol) of 89 and 60 minutes per day prior and after the 
use of real time CGM. Participants in the present study spent 40 and 49 minutes per 
day during closed loop and control periods; excluding subjects with significant co-
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morbidities and hypoglycaemia unawareness may have led to selection of 
participants with a lower hypoglycaemia risk.    
A smart phone based closed-loop control platform was previously evaluated in 
20 adults in four clinical centres in a non-randomised single arm study design in a 
home like environment (hotel / guest house or mixed hospital-hotel admissions) (33). 
The study duration was 42 hours with first 14 hours of operation under open loop 
control followed by 28 hours of closed-loop. In contrast, out-patient closed-loop 
duration in the present study was longer at 168 hours per participant. Two further 
randomised crossover studies have evaluated the use of overnight closed-loop 
outside clinical research facility. The first study showed reduced rates of 
hypoglycaemia during a single night at three youth diabetes camps (34). An interim 
analysis from the second study using closed-loop at home for four nights have also 
shown reduced hypoglycaemia burden (35). Feasibility of dual hormone closed-loop 
under free living conditions at home for 48 hours have been evaluated but despite 
the use of glucagon this study reported more hypoglycaemia during closed-loop arm 
(36). 
During the present proof-of-concept study, a prototype closed-loop system 
was used with the objective to assess the feasibility of day and night hybrid closed-
loop. Participants were required to carry the ultra-portable computer in a removable 
pouch. When CGM was available closed-loop was operational over 90% of time 
during the home phase. Based on encouraging results from the current study, a 
closed-loop system based on smart phone technology suitable for longer studies is 
under development. During current study, there was no dedicated treatment 
optimisation period and participants were only informed about insulin requirements in 
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each study period after completion of the study minimising any influence arising from 
the cross over study design.    
Training on closed-loop system took about 60 minutes. Closed-loop 
technology appears simple to initiate once insulin pump therapy and continuous 
glucose monitoring is established. A more comprehensive training was administered 
at study start, to familiarise participants with the study pump and continuous glucose 
monitoring. The two severe hypoglycaemic events seen during current study were 
unrelated to closed-loop insulin delivery.  
The strengths of our study are the integration of closed-loop into normal life 
including use at work, weekends, holidays, varied diet and sleeping patterns and 
randomised crossover study design in multinational multicentre settings. Participants 
started and stopped closed-loop without supervision.. Weaknesses include a small 
sample size, an early generation closed-loop system (which is not a commercially 
available product), and a relatively short study duration.  
In conclusion, day and night closed-loop can be used safely at home and its 
benefits include increased time when glucose is in target and reduced mean glucose. 
Larger and longer studies are warranted. 
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Table 1: Glucose control during closed-loop and sensor augmented pump therapy 
over the seven day home phase and one-day stay at the clinical research facility in 
17 patients with type 1 diabetes. 
 
 Closed-loop 
 
SAP 
 
P* 
Free living conditions (7 days) - based on CGM 
Mean glucose (mmol/l)** 8.1 ± 1.0 8.8 ± 1.0 0.027 
SD of glucose (mmol/l)** 2.9 ± 0.6 3.3 ± 0.8 0.034 
CV of glucose (%) ** 35.7 ± 5.9 37.7 ± 7.6 0.149 
Time spent at glucose level (%)    
 3.9 to 10.0 mmol/l≠ 74.5 (61.1, 78.9) 61.8 (53.3, 70.1) 0.005 
 3.9 to 10.0 mmol/l** 75.3 (62.1, 82.0) 62.6 (54.8, 72.4) 0.006 
 3.9 to 8.0 mmol/l≠ 54.9 (42.2, 58.3) 43.3 (33.0, 49.1) 0.017 
 >10.0 mmol/l≠ 21.9 (16.7, 32.3) 30.5 (24.3, 41.4) 0.013 
 >16.7 mmol/l≠ 1.5 (0.5, 3.5) 3.3 (1.4, 5.0) 0.049 
 <3.9 mmol/l≠ 3.7 (2.2, 7.9) 5.0 (2.3, 8.5) 0.339 
 <2.8 mmol/l≠ 0.3 (0.2, 1.1) 0.6 (0.2, 1.6) 0.124 
AUCDAY <3.5 mmol/l**   (mmol/l × 
minutes) 
2.9 (1.4, 15.8) 7.9 (1.3, 24.1) 0.149 
LBGI** 0.6 (0.5, 1.4) 0.9 (0.5, 1.5) 0.309 
HBGI** 4.5 (3.3, 7.2) 7.2(4.8, 9.1) 0.039 
Clinical research facility (one day) - based on YSI glucose 
Mean glucose (mmol/l) 8.2 ± 1.0 8.6 ± 1.6 0.292 
SD of glucose (mmol/l) 2.4 ± 0.7 2.8 ± 0.7 0.079 
CV of glucose (%) 27.5 ± 8.3 33.0 ±8.4 0.095 
Time spent at glucose level (%)    
 3.9 to 10.0 mmol/l 73.7 (63.4, 84.1) 60.7 (49.2, 76.8) 0.044 
 <3.9 mmol/l 1.8 (0, 5.8) 4.7 (0, 7.8) 0.221 
 >10.0 mmol/l 21.4 (13.6, 33.5) 24.5 (16.0, 49.1) 0.124 
 Data shown are mean ± SD or median (IQR), *Paired samples t-test or Wilcoxon signed Rank Test.  
**
 Based on native CGM, 
≠
 Adjusted for CGM measurement error assuming a relative absolute 
deviation of 15%, 
**
 Based on native CGM  
SAP= sensor augmented pump therapy; LBGI and HBGI=low and high  blood glucose index; 
CGM=continuous glucose monitoring, AUC – area under the curve calculated per day 
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Table 2: Insulin delivery and day-time and night-time glucose control during the home 
phase.   
 Closed loop 
 
SAP 
 
P* 
Insulin delivery  
Total basal (U) / day 20.1 (17.2, 24.7) 18.9 (15.4, 20.4) 0.017 
Total bolus (U) / day 18.9 (15.5, 25.5) 26.5 (20.6, 30.1) 0.002 
Total daily dose (U) 39.1 (34.7, 45.7) 44.7 (36.3, 51.0) 0.109 
SD of basal insulin  0.7 (0.6, 0.9) 0.2 (0.1, 0.2) <0.001 
Day-time and night-time glucose control  
Day-time (07:00 till 22:59 hours) 
Mean glucose 8.1 ±1.0 8.5 ± 1.2 0.147 
Time in target (3.9 to 10 
mmol/l)≠  
72.5 (63.4, 78.6) 65.4 (54.6, 71.0) 0.017 
AUCDAY below 3.5 mmol/l      
(mmol/l × minutes) 
2.3 (0.9, 19.3) 6.3(0.4, 30.1) 0.225 
Night-time (23:00 till 06:59 hours) 
Mean glucose 8.3 ± 1.3 9.3 ± 1.1 0.015 
Time in target (3.9 to 8 mmol/l) ≠  48.4 (32.5, 64.5) 35.1 (28.4, 47.5) 0.013 
AUCDAY below 3.5 mmol/l     
(mmol/l × minutes) 
3.1 (0, 17.5) 3.2 (0.1, 33.5) 0.163 
Data shown are mean ± SD or median (IQR) *Paired samples t tests or Wilcoxon signed rank test. 
AUC – area under the curve calculated per day, SD - Standard deviation, SAP - sensor augmented 
pump therapy.  
≠
 Adjusted for CGM measurement error assuming a relative absolute deviation of 15%. 
*Paired samples t-test or Wilcoxon signed rank test. 
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Figure Legends 
 
 
 
 
 
1. Figure 1: 24 h Glucose profiles during home use of closed-loop and sensor 
augmented pump therapy. The target glucose range 3.9 to 10.0 mmol/l is 
denoted by the dashed lines. Data shown are median (interquartile range). 
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2. Figure 2: Time spent in target glucose range 3.9 to 10.0 mmol/l by participants 
(N=17) at home. Fourteen (82%) participants showed increased time in target 
range during closed-loop compared to sensor augmented pump therapy 
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